Niacin can not prevent heart attacks
On Thursday the National Institutes of Health(NIH) halted a major research of high-dose NIACIN, a kind of B vitamin, more than a year forward of schedule as a consequence of the lack of advantage. It had been the newest setback inside the quest to harness great cholesterol to fight the undesirable type.
The trial, sponsored through the U.S. National Institutes of Health plus a drug maker, enrolled patients with a historical past of heart disease who had their “bad” LDL cholesterol below handle with statin drugs. The brand new trial hoped to make use of niacin (also called vitamin B3) to boost ranges of “good” HDL cholesterol while lowering blood amounts of fats named triglycerides to help you reduce the odds of heart attack or stroke.
The most recent study tested Abbott Laboratories’ Niaspan, an extended-release sort of niacin that is a far larger dose than is discovered in dietary supplements. The drug has long been sold for years, and prior studies have proven it does enhance HDL levels.
Read more detail at:
